Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7

Journal of Biotechnology

Volumn 154, Issue 1, 2011, Pages 84-92

  Pasche, Nadine ^a   Woytschak, Janine ^a   Wulhfard, Sarah ^a   Villa, Alessandra ^a   Frey, Katharina ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

F8 antibody; Immunocytokine; Interleukin 7; Targeting

Indexed keywords

ANTIBODY FRAGMENT; ANTICANCER ACTIVITIES; C-TERMINUS; CLINICAL TRIAL; DOSE DEPENDENCES; F8 ANTIBODY; FUSION PROTEINS; IMMUNOCYTOKINE; IN-VIVO; INTERLEUKIN 7; ISOFORMS; PACLITAXEL; PHARMACEUTICAL QUALITY; TARGETING; TUMOR GROWTH; TUMOR TARGETING;

ANTIBODIES; CLONING;

TUMORS;

HYBRID PROTEIN; IMMUNOCYTOKINE F8 MIL7; IMMUNOCYTOKINE F8 MIL7 F8; INTERLEUKIN 7; PACLITAXEL; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TERATOCARCINOMA;

ANIMALS; CLONING, MOLECULAR; HUMANS; INTERLEUKIN-7; IODINE RADIOISOTOPES; MICE; NEOPLASMS; PACLITAXEL; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TISSUE DISTRIBUTION;

MURINAE; MUS;

EID: 79957437540     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.04.003     Document Type: Article

References (48)

1. Alpdogan O., Muriglan S.J., Eng J.M., Willis L.M., Greenberg A.S., Kappel B.J., van den Brink M.R. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. The Journal of clinical investigation 2003, 112:1095-1107.
2. Alpdogan O., Schmaltz C., Muriglan S.J., Kappel B.J., Perales M.A., Rotolo J.A., Halm J.A., Rich B.E., van den Brink M.R. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 2001, 98:2256-2265.
3. Aoki T., Tashiro K., Miyatake S., Kinashi T., Nakano T., Oda Y., Kikuchi H., Honjo T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3850-3854.
4. Borger P., Kauffman H.F., Postma D.S., Vellenga E. IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. Journal of Immunology 1996, 156:1333-1338.
5. Chazen G.D., Pereira G.M., LeGros G., Gillis S., Shevach E.M. Interleukin 7 is a T-cell growth factor. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:5923-5927.
6. Conlon P.J., Morrissey P.J., Nordan R.P., Grabstein K.H., Prickett K.S., Reed S.G., Goodwin R., Cosman D., Namen A.E. Murine thymocytes proliferate in direct response to interleukin-7. Blood 1989, 74:1368-1373.
7. Cosenza L., Sweeney E., Murphy J.R. Disulfide bond assignment in human interleukin-7 by matrix-assisted laser desorption/ionization mass spectroscopy and site-directed cysteine to serine mutational analysis. The Journal of Biological Chemistry 1997, 272:32995-33000.
8. Cytheris Inc., 2011a. Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant, In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 10.03.2011] ed. NLM Identifier: Available from: http://clinicaltrials.gov/ct2/show/NCT00684008.
9. Cytheris Inc., 2011b. Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer, In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 10.03.2011] ed. NLM Identifier: Available from: http://clinicaltrials.gov/ct2/show/NCT00492440.
10. Ebbinghaus C., Ronca R., Kaspar M., Grabulovski D., Berndt A., Kosmehl H., Zardi L., Neri D. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. International Journal of Cancer 2005, 116:304-313.
11. Frey K., Schliemann C., Schwager K., Giavazzi R., Johannsen M., Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. The Journal of Urology 2010, 184:2540-2548.
12. Frey K., Zivanovic A., Schwager K., Neri D. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integrative Biology: quantitative biosciences from nano to macro 2011, 3:468-478.
13. Fry T.J., Mackall C.L. Interleukin-7: from bench to clinic. Blood 2002, 99:3892-3904.
14. Gafner V., Trachsel E., Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. International Journal of Cancer 2006, 119:2205-2212.
15. Gringhuis S.I., de Leij L.F., Verschuren E.W., Borger P., Vellenga E. Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1. Blood 1997, 90:2690-2700.
16. Halin C., Gafner V., Villani M.E., Borsi L., Berndt A., Kosmehl H., Zardi L., Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Research 2003, 63:3202-3210.
17. Halin C., Rondini S., Nilsson F., Berndt A., Kosmehl H., Zardi L., Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nature Biotechnology 2002, 20:264-269.
18. Helguera G., Morrison S.L., Penichet M.L. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clinical Immunology (Orlando, FL) 2002, 105:233-246.
19. Hock H., Dorsch M., Diamantstein T., Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. The Journal of Experimental Medicine 1991, 174:1291-1298.
20. Holliger P., Prospero T., Winter G. Diabodies small bivalent and bispecific antibody fragments. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:6444-6448.
21. Johannsen M., Spitaleri G., Curigliano G., Roigas J., Weikert S., Kempkensteffen C., Roemer A., Kloeters C., Rogalla P., Pecher G., Miller K., Berndt A., Kosmehl H., Trachsel E., Kaspar M., Lovato V., Gonzalez-Iglesias R., Giovannoni L., Menssen H.D., Neri D., de Braud F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. European Journal of Cancer 2010, 46:2926-2935.
22. Kaspar M., Trachsel E., Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Research 2007, 67:4940-4948.
23. Komschlies K.L., Gregorio T.A., Gruys M.E., Back T.C., Faltynek C.R., Wiltrout R.H. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. Journal of Immunology 1994, 152:5776-5784.
24. Marlind J., Kaspar M., Trachsel E., Sommavilla R., Hindle S., Bacci C., Giovannoni L., Neri D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clinical Cancer Research 2008, 14:6515-6524.
25. Miller A.R., McBride W.H., Dubinett S.M., Dougherty G.J., Thacker J.D., Shau H., Kohn D.B., Moen R.C., Walker M.J., Chiu R., et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood 1993, 82:3686-3694.
26. Miller P.W., Sharma S., Stolina M., Butterfield L.H., Luo J., Lin Y., Dohadwala M., Batra R.K., Wu L., Economou J.S., Dubinett S.M. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Human Gene therapy 2000, 11:53-65.
27. Morrissey P.J., Goodwin R.G., Nordan R.P., Anderson D., Grabstein K.H., Cosman D., Sims J., Lupton S., Acres B., Reed S.G. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. The Journal of Experimental Medicine 1989, 169:707-716.
28. Mortara L., Balza E., Sassi F., Castellani P., Carnemolla B., De Lerma Barbaro A., Fossati S., Tosi G., Accolla R.S., Borsi L. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. European Journal of Immunology 2007, 37:3381-3392.
29. Muller N., Derouazi M., Van Tilborgh F., Wulhfard S., Hacker D.L., Jordan M., Wurm F.M. Scalable transient gene expression in Chinese hamster ovary cells in instrumented and non-instrumented cultivation systems. Biotechnology Letters 2007, 29:703-711.
30. Namen A.E., Lupton S., Hjerrild K., Wignall J., Mochizuki D.Y., Schmierer A., Mosley B., March C.J., Urdal D., Gillis S. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988, 333:571-573.
31. Namen A.E., Schmierer A.E., March C.J., Overell R.W., Park L.S., Urdal D.L., Mochizuki D.Y. B cell precursor growth-promoting activity purification and characterization of a growth factor active on lymphocyte precursors. The Journal of Experimental Medicine 1988, 167:988-1002.
32. National Cancer Institute, USA, 2011. Interleukin-7 in Treating Patients With Refractory Solid Tumors, In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 10.03.2011]. ed. NLM Identifier: Available from: http://clinicaltrials.gov/ct2/show/NCT00062049.
33. Pedretti M., Verpelli C., Marlind J., Bertani G., Sala C., Neri D., Bello L. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. British Journal of Cancer 2010, 103:827-836.
34. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., Stetler-Stevenson M., Morton K.E., Mavroukakis S.A., Morre M., Buffet R., Mackall C.L., Gress R.E. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. Journal of Immunotherapy 2006, 29:313-319.
35. Rybak J.N., Roesli C., Kaspar M., Villa A., Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Research 2007, 67:10948-10957.
36. Schliemann C., Neri D. Antibody-based targeting of the tumor vasculature. Biochimica et Biophysica Acta 2007, 1776:175-192.
37. Schliemann C., Palumbo A., Zuberbuhler K., Villa A., Kaspar M., Trachsel E., Klapper W., Menssen H.D., Neri D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009, 113:2275-2283.
38. Schliemann C., Wiedmer A., Pedretti M., Szczepanowski M., Klapper W., Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leukemia Research 2009, 33:1718-1722.
39. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nature Reviews 2006, 5:147-159.
40. Schwager K., Kaspar M., Bootz F., Marcolongo R., Paresce E., Neri D., Trachsel E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Research and Therapy 2009, 11:R142.
41. Sharma S., Batra R.K., Yang S.C., Hillinger S., Zhu L., Atianzar K., Strieter R.M., Riedl K., Huang M., Dubinett S.M. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Human Gene Therapy 2003, 14:1511-1524.
42. Silacci M., Brack S., Schirru G., Marlind J., Ettorre A., Merlo A., Viti F., Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005, 5:2340-2350.
43. Sommavilla R., Pasche N., Trachsel E., Giovannoni L., Roesli C., Villa A., Neri D., Kaspar M. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Engineering, Design and Selection 2010, 23:653-661.
44. Spitaleri G., Pas T.D., Noberasco C., Giovannoni L., Menssen H.D., Toffalorio F., Catania C., Milani A., Borselli S., Neri D., Braud F.d. Phase I study of the tumor-targeting human L19TNF monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. Annals of Oncology 2010, 21(Suppl. 8):viii 162-viii 184.
45. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., Brown M.R., Fleisher T.A., Noel P., Maric I., Stetler-Stevenson M., Engel J., Buffet R., Morre M., Amato R.J., Pecora A., Mackall C.L., Gress R.E. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clinical Cancer Research 2010, 16:727-735.
46. Tarli L., Balza E., Viti F., Borsi L., Castellani P., Berndorff D., Dinkelborg L., Neri D., Zardi L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94:192-198.
47. Vella A.T., Dow S., Potter T.A., Kappler J., Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3810-3815.
48. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., Rosli C., Borsi L., Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. International Journal of Cancer 2008, 122:2405-2413.